In this video, Marco Zarbin, MD, PhD, reports on a post-hoc analysis of HARBOR clinical trial data, in which  subretinal fluid, persistent in spite of aggressive anti-VEGF treatment, was associated with a reduced risk of progression to atrophy.  He hypothesizes that subretinal fluid could be the expression of an imperfect but perhaps critical survival strategy that maintains the function of the degenerating macula.